Study selection
The initial search yielded 3608 articles, after removing duplicates (n = 32), 3576 studies underwent title and abstract screening. The full texts of 500 articles were retrieved for eligibility assessment, and 474 articles were excluded for the following reasons: outside India (n = 198), not reporting kidney outcome (n = 36), case reports (n = 110), review articles (n = 88), a systematic review from another continent (n = 1), a systematic review on cardiovascular outcomes and aetiology (n = 2), study reporting outcomes only in pre-eclampsia cases (n = 1) and conference abstracts (n = 40). Finally, a total of 2306 patients across 25 studies were included in the final analysis. (10–34), See Fig. 1 for PRISMA flowchart.
Baseline characteristics
The incidence of PRAKI in Indian studies has varied, ranging from 1.08–12% of AKI cases reported by different centres. Jaiprakash et al. and Sachan et al. reported AKI incidence rates of 2.73% and 1%, respectively, among all pregnancies during their study periods (23, 30). The baseline characteristics of the included studies are provided in Table 1.
The patient population in the included studies varied from 27 to 395 individuals, with the majority being conducted in government hospitals. However, one study was conducted at a private tertiary care centre. (16) All the studies were single-centre and 8 out of 25 studies were retrospective in design. (13, 16, 17, 20, 22, 24, 27, 29). The third trimester or postpartum period was identified as the most common phase for the presentation of PRAKI with up to 80% of cases occurring during this time. Notably, Najar et al. reported a significant number of early-trimester AKI cases (75%). (11) There was a general predominance of multigravida patients in the reviewed studies. The criteria for defining AKI were not uniform across the studies; only 9 studies applied the KDIGO AKI criteria for staging. (18, 24, 26, 27, 29, 30, 32, 33, 34). In contrast, other studies defined AKI based on oliguria or an increase in serum creatinine levels. Additionally, six studies focused exclusively on postpartum AKI cases. (16, 19, 20, 24, 25, 27)
Etiology of PRAKI
Sepsis was found to be the most frequent cause of PRAKI, ranging from 13.9–78.8% across different cohorts. (See Table 2) Puerperal sepsis was commonly reported, constituting the primary cause of sepsis in many studies, while post-abortal sepsis also contributed significantly in some. (10, 11, 16, 17 ), Najar et al. reported septic abortion as the most common cause accounting for 20 (50%) of the women with PRAKI, 15 (75%) of which occurred in the first trimester and five (25%) in the second trimester. Of 20 patients with septic abortion, 18 (90%) were from rural areas and their abortions had been conducted by untrained midwives. (11) Pre-eclampsia and eclampsia, another significant contributor to PRAKI, appeared frequently in multiple studies, with incidences ranging from 14–46.9%. Gopalakrishnan et al. reported a 21% incidence of pre-eclampsia/eclampsia, (18) while Prakash et al. found it in 46.9% of cases. (23) In addition, HELLP syndrome was a contributing factor in certain cases, with incidences as high as 44.45% reported by Kharkongor et al. (33) Obstetric hemorrhages such as antepartum haemorrhage (APH) and postpartum haemorrhage (PPH) were also prevalent in many of the studies. Krishna et al. found that 23.4% of patients experienced APH and PPH, (17) while Sahay et al. reported a combined incidence of 44.5%. (29) Other studies, such as those by Sandilya et al. and Kharkongor et al., reported significant occurrences of hemorrhage-related complications, which were often associated with sepsis or pre-eclampsia. (32–33) Glomerular diseases contributed to 0.7 to 5.8% of PRAKI cases. The most common aetiology was lupus nephritis. Several other etiologies were noted across the reviewed studies, including malaria, snake bite, acute gastroenteritis, hemolytic uremic syndrome (HUS), and acute fatty liver of pregnancy (AFLP). Out of total of 2306 case of PRAKI, AFLP was only due to 18 cases. Only 3 cases were contributed by obstructive etiology.
Table 2
Etiologies of Pregnancy associated acute Kidney Injury
Sl, number | First author | Sepsis (n%) | Sepsis Etiology | APH (n%) | Pre-eclampsia/Eclampsia (n%) | PPH (n%) | Glomerular Disease (n%) | HELLP (n%) | AFLP (n%) | Others with Etiology |
1 | Goplani KR et al, (10) | 57 (71%) | Puerperal sepsis − 43 and post abortal-14 | 10 (14.28%) | 20 (28.57%) (includes HELLP) | 17 (24.28%) | NR | NR | NR | Malaria (3) (4.28%) |
2 | Najar MS et al, (11) | 20 (50%) | Abortion, Acute pyelonephritis-2 (5%), | 6 (15%) | 6 (15%) | 2 (5%) | NR | NR | NR | AGE-3 (7.5%) |
3 | Arora N et al, (12) | 19 (33.3%) | Puerperal sepsis (100%) | - | PE/other hypertensive disorder-7 (12.3%), Eclampsia-8 (14.0%) | 16 (28.1) | NR | NR | NR | Snake bite-2 (3.5%), Perioperative hypotension-1 (1.7%), HUS-1 (1.7%), Unknown-3 (5.3%) |
4 | Sivakumar V et al, (13) | 28 (47.41%) | Puerperal sepsis: 28 (47.41%) | 5 (8.47%) | 17 (30.50%) | 6 (10.16%) | NR | NR | NR | Miscellaneous (18.64%) |
5 | Patel ML et al (14) | 25 (41.7%) | Post partum sepsis | 4 (6.66%) | 20 (33.3%) | 4 (6.66%) | - | 1 (1.7%) | - | Abortion-5 (8.3%), DIC-1 (1.7%) |
6 | Pahwa N et al, (15) | 19 (70.3%) | Puerperal sepsis: 9 (29.7%) UTI: 5 (18.5%) | 2 (10%) | 2 (10%) | 1 (6%) | NR | 2 (8.4%) | NA | HUS-2 (9%) |
7 | Godara SM et al, (16) | N = 44 (78.8%) | Puerperal sepsis: 44 (63.1%), post-abortion sepsis: (4) 15.7% | 7 (14%) | 14 (33.33%) | 2 (8.7%) | FSGS − 1(1.75%), MPGN-1 (1.75%) | NR | NR | Malaria 3(5.2%), |
8 | Krishna A et al, (17) | 55 (56.1%) | Post abortal | PPH + APH-23 (23.4%) | 14 (14.2%) | NR | NR | 4 (4.08%) | HUS-2 (2.04%) | NR |
9 | Gopalakrishnan N et al, (18) | 51 (39%) | Septic abortion-4 (7.84%), Puerperal sepsis − 47 (92.15%) | 13 (10%) | 27 (21%) | 3 (2%) | 4 (3%) | 5 (3.84%) | NR | Acute Diarrhea-13 (10%), TMA-11 (9%), Others-3 (2.30%) |
10 | Gullipali et al, (19) | 16 (33.33%) | Puerperal sepsis in all cases of sepsis | 2(4.16%) | 12(25%) | 6 (12.5%), | 5 (10.41%) | 12(25%) with pre eclampsia | NR | Complicated malaria: 3(6.25%) |
11 | Eswarappa et al, (20) | 74 (75%) | Puerperal sepsis: 60.6%(n = 61) UTI: 6 (6%) Septic thrombophlebiitis 1 (1%) Necrotizing fascitis 1 (1%) Mucormycosis 1 (1%) | NR | NR | 12% (n = 14) | LN-1 (1%), | n = 10 (8%) along with preeclampsia | None | HUS-1 (1%),Transfusion reaction − 1(1%), Isolated postpartum PIH-1 (1%) H1N1: 1 (1%) |
12 | Mishra V et al, (21) | 17 (32.6%) | Post abortal-3 (5.77%) Peurperal-8 (15.38%), Combined hemorrhage and sepsis : 9 (17.30%). | 9 (17.30%) | PE-31 (59.6%), Eclampsia-4 (7.69%) | 11 (21.15%) | - | 1 (1.92%) | 1 (1.92%) | Malaria, IUD with sepsis |
13 | Prakash J et al, (22) | 39 (15%) | Puerperal sepsis: 39 (15%) | (APH + PPH) 25 (9.65%) | PE + HELLP: 41 (15.8%) | NR | LN : 2 (0.07%) | NR | 1 (0.06%) | 152 (58.68%) Post abortal, HUS : 1 (0.06%) |
14 | Prakash J et al, (23) | 42 (31.8%) | Puerperal sepsis-34 (25.8%), Post abortal sepsis-8 (6.1) | 11 (8.3%) | 62 (46.9%) | 28 (21.2%) | 1 (0.75%)-LN | 9 (6.8%) | 5 (3.8%) | Fulminant hepatitis-4 (3.03%), Acute gastroentritis-3 (2.27%), UTI-2 (1.5%), Complicated malaria-1 (0.75%) |
15 | Mir M et al, (24) | 11 (39.28%) | Puerperal sepsis : 11 (39.28%) Acute pyelonephritis-3 (11%) | NR | 4 (14%) | 7 (25%) | ANCA-1 (4%), | NR | NR | HUS-1 (4%) |
16 | Tanwar et al, (25) | 31(61.6%) | Puerperal sepsis: 31(61.6%) | 14 (23.3%) | 21 (35%) | 7 (11.7%) | NR | 3 (5%) | 4( 6.7% ) | Tropical infections, malaria- 02 (5%), TMA − 2 (3.3%), Hemorrhage in early pregnancy (8.7%) Dengue hemorrhagic fever, N = 1 |
17 | Saini et al, (26) | 42 (49.4%) | Puerperal sepsis: 41 (49%) | NR | 13 (12.3%) | 12 (16%)) | NR | 3 (4.9%) | 2 (2.4%) | Malaria (1.2%), Unexplained (1.2%) P-aHUS : 14 (17.28% ) |
18 | Chowdhary PK, (27) | 35 (32.71%) | Puerperal sepsis, RPOC-6 (17.14%), UTI-22 (62.85%), Pneumonia-6 (17.14%), Abdominal wound-5 (14.28%), Episiotomy wound-3 (8.57%) | NR | 8 (7.47%) | 4 (3.73%) | 2 (1.86%) | NR | 1 (0.93%) | HUS, N = 1 |
19 | Banerjee A et al, (28) | 5 (13.9%) | Bacterial sepsis : 5 (13.39) Viral sepsis: 3 (3.33%) | NR | 13 (36.11%) | Total 4 (11.11%) hemorrhage cases | None | 1 (2.72%) | 2 (5.56%) | Hyperemesis gravidarum: 2 (5.56%), Malaria: 4 (11%), Dengue :1 (2.72%), Snake bite: 1 (2.72%) |
20 | Sahay M et al, (29) | 132 (33.41%) | NR | 31 (8%) | 176 (44.5%) | 46 (12%) | 11 (2.7%) | GN 11 (10.6%) | NR | 9 (8.7%)-HUS Obstruction: n = 2 |
21 | Sachan R et al, (30) | 68 (45.3%) | Puerperal sepsis, n = 64 (42.6) Septic abortion, 4 (2.6%) | 15 (10%) | HDP: 72 (48%) PE-30 (20%) / EC-42 (28%) | 39 (26%) | NR | NR | NR | AGE : n = 2, Liver dysfunction n = 11, Heart diseases, n = 2 Caogulopathy, n = 25 |
22 | Yadav S et al, (31) | 21(18.1%) | Puerperal Sepsis | - | PE- 14 (39%) Eclampsia – 8(13%) | NR | NR | 6 (16.6%) | NR | AGE − 01 (3%) |
23 | Sandilya S, (32) | 12 (24%) | Puerperal sepsis: 12 (24%) Pyelonephritis : 2 (4%) | Abruption :7(14%) | 14 (28%), | 10 (20%) | NR | NR | NR | TMA : 1 (2%) |
24 | Kharkongor D et al, (32) | 31 (28.18%) | Puerperal + postabortal + sepsis: 31 (28.18%) | APH + PPH + post abortal: 39 (35.45%) | PE/Eclampsia/HELLP: 49 (44.45%) | APH + PPH 49 (44.54%) | NR | PE/Eclampsia/HELLP: 49 (44.45%) | 12 (10.91%) | Others: 3 (2.72) |
25 | Saxena D et al, (34) | 20 (29.4%) | NR | 1 (1.4%) | 9 (13.2%) | 18 (26.4%) | 4 (5.8%) | 2 (2.9%) | NR | Obstructive uropathy, n = 1 (1.4%) |
AFLP: Acute fatty liver of pregnancy, HUS: hemolytic uremic syndrome, APH: Antepartum haemorrhage, PPH: Antepartum haemorrhage, HELLP: Hemolysis, Elevated Liver enzymes and Low Platelets, RPOCs: retained products of conception, PE : Pre-eclampsia, TMA: Thrombotic microangiopathy, AGE: Acute Gastroenteritis, UTI: Urinary tract infection, HDP: Hypertensive disorders of pregnancy |
Renal outcome
Renal outcomes in PRAKI varied considerably across studies, with a significant proportion of patients requiring renal replacement therapy (RRT) up to 85%, including hemodialysis (HD) and peritoneal dialysis (PD), as well as long-term impacts such as chronic kidney disease (CKD) and dialysis dependency. See Table 3. In the majority of the studies, hemodialysis modality was used, in only 3 studies use of PD was reported. (20, 24, 25). For instance, in the cohort by Goplani et al., 97.14% of patients underwent HD, and 85.9% achieved full recovery, though 12.85% progressed to CKD, and 14.28% became dialysis dependent. (10) Similarly, Najar et al. found that 40% of their patients required dialysis, with 72.5% achieving full recovery, while only 5% developed CKD. (11)
Table 3
Renal outcomes HD: Hemodialysis, ATN: acute tubular necrosis, ATIN: Acute tubulointerstitial nephritis, ACN: Acute cortical necrosis, TMA: Thrombotic microangiopathy, CRRT: Continuous Renal Replacement Therapy, FSGS: focal and segmental glomerulosclerosis, MPGN: membranoproliferative glomerulonephritis, MGN: membranous glomerulonephritis, PD: Peritoneal dialysis, LN: Lupus nephritis, GN: Glomerulonephritis, CVVHDF: Continuous venovenous hemodiafiltration,
Sl, number | First author | Renal biopsy | RRT modality | Dialysis requirement | Full revovery | CKD development | Dialysis dependant |
1 | Goplani KR et al, (10) | Performed in 11 (N = 11)patients ACN: 10 Glomerular endotheliosis-1(associated with preeclampsia) | 89, (97.14)% -HD 8 (8.6%) patients received PD initially and later shifted to HD. | 49 (85.9%) | 38 (54.28%) | 9 (12.85%) | 10(14.28%) |
2 | Najar MS et al, (11) | NR | HD: 13 (32.5%) PD: 6(15%) and both modalities to 5 (12.5%) | 24(40%) | 29 (72.5%) | 2 (5%) | 1 (2.5%) |
3 | Arora N et al, (12) | Renal Biopsy in patients ATN: 2, ACN: 3, subacute interstitial nephritis :1 Inconclusive 1 | 100% HD | 49 (6.9%) | 24 (50) | 5 (8) | 3(5.2) |
4 | Sivakumar V et al, (13) | NR | HD 29 (49.15%), CVVHD 4 (6.77%), PD 3 (3.38%) | 35 (59.3%) | 31 (54.23%) | 6 (10.16%) | NR |
5 | Patel ML et al (14) | NR | Hemodialysis- 23 (38.33%) | 23(38.33%) | 45 (75%) | 1 (1.7%) | 5 (8.3%) |
6 | Pahwa N et al, (15) | N = 11 (18.5%) ACN 5, | All HD | 25 (92%) | 11(40. 7%) | 6(22.2%) | 2(7.4%) |
7 | Godara SM et al, (16) | N = 21 (36.84%) ACN : n = 13 (61.9%), ATN n = 4, Glomerular disease (n = 3,) FSGS-1. MPGN-1 MGN-1 ATIN-1 | HD: 50 (87.7%), PD :3 (5.2%) | 50 (87.7%) | 50 (52.64%) | 12 (21.05%) | 15 (26.31%) |
8 | Krishna A et al, (17) | N = 16 ACN- 8 ACN(patchy) + TMA − 6 ATN − 2 | HD: 98 (100%) | 24 (24.49%)1 session HD 74 (75.5%)-multiple sessions | 53 (54.28%) | 13 (12.85%) | 14 (14.28%) |
9 | Gopalakrishnan N et al, (18) | N = 46 (35.3%), ACN: 16 (34.7%), TMA: 11 (23.9%), ATN: 9 (19.5), ATIN: 1 Glomerular disease- 9 (Lupus nephritis 4 IgA nephropathy 1 Diffuse mesangial proliferation 1 Focal segmental glomerulosclerosis 1 Pauci-immune necrotising GN 1 Infection-related GN- 1) | All HD | 96 (74%) | 73 (56%) | 46 (35%) | 1(7.69%) |
10 | Gullipali et al, (19) | N = 15 (31.2%) ACN: 6 (12.5) LN : 4 (8.3) TMA: 3 (6.24%) FSGS : 1 (2.08%) ATN: 1 (2.08%) | HD in all patients | 23(47%) | 38 (79.4%) | 2 (4.1%) | 4(8.3%) |
11 | Eswarappa et al, (20) | NR | HD: 29 (29%), PD :6(6%), CRRT : 4 (4%) | 39 (39%) | 70 (70%) | 5 (5%) | 3 (3%) |
12 | Mishra V et al, (21) | N = 10 ACN- 8 ATN- 2 | All HD | 43 (84.62%) | 29 (55.76%) | 19 (50%) | 4(7.69%) |
13 | Prakash J et al, (22) | N = 18 Diffuse ACN 8 Patchy ACN 7 Glomerular disease-2, both LN Changes of CKD- 1 | All HD | 223 (86.1%) | 199 (76.83%) | 28 /259 (10.8%) | 7 (2.7%) |
14 | Prakash J et al, (23) | N = 4 ACN:N = 3, LN: N = 1 | All HD | 62 (47%) | 118 (89.4%) | 8(6.06%) | 6 (4.6%) |
15 | Mir M et al, (24) | N = 9 (14.7) ACN n = 4(44.44). ATN: n = 3 (33.33) Glomerular disease : 1 (pauci-immune GN)(11.11), TMA: 1 (11.11) | 9 (33%) HD and 4 (14%)-PD | 13(46%) | 15(54%) | 6(21%) | 4(14%) |
16 | Tanwar et al, (25) | N = 11 (18.3%) ACN: 6, ATN: 2 TMA: 2 Inconclusive: 1 | HD :54 (90%), PD : 25(41.7%), | 100% | NR | 31 (51.3%) | 2(5.4%) |
17 | Saini et al, (26) | N-24(30%) TMA: 13 (54%) ACN:4 (17) ATN: 6(25) Diffuse Glomeruloscleorsis: 1 (4%) | HD: 68 (84%) | 68 (84%) | 27 (39%) | 23 (33%) | 11 (16%) |
18 | Chowdhary PK, (27) | N = 7(6.54%) patients ATN:n = 3 ACN: N = 3, and TMA: n = 1 | All HD | 73 (68.22%) | 75 (88.2%) | 6(7.05%) | 4(4.7%) |
19 | Banerjee A et al, (28) | NR | All HD | Only dialysis patients included | NR | NR | Total n = 3 (8.3%) Early RRT group-2(15.38%), Standard RRT group-1(4.35%) |
20 | Sahay M et al, (29) | N = 103 Patchy cortical necrosis 25 (22.3%), Diffuse ACN 23 (20.3%), ATN 20 (19.4%), AIN 10 (9.7%), TMA 9 (8.7%), GN 11 (10.6%), IgA n = 4, MPGN,n = 2, FSGS n = 2, LN n = 3, endotheliosis, n = 2 | All HD | 290(73.6%) | 285 (76%) | 59 (15.7%) | 31 (8.3%) |
21 | Sachan R et al, (30) | NR | HD | 98(65.33%) | 41(27.3%) | 46(31.3%) | 5(3.39%) |
22 | Yadav S et al, (31) | NR | NR | 14 (27.5%) | 33 (64.7%) | 6 (12%) | NR |
23 | Sandilya S, (32) | NR | HD | 23 (46%) | 40 (80%) | 10 (20%) | NR |
24 | Kharkongor D et al, (32) | NR | HD | 29 (26.4%) | 45(40.9%) | 25 (22.7%) | 10 (9.1%) |
25 | Saxena D et al, (34) | N = 33 Diffuse ACN-14 Patchy ACN − 6 ATN − 9 Glomerular disease − 4 | HD | 62 (72.1) | 21 (38.2%) | 15 (30%) | 16 (32%) |
Outcomes also varied significantly regarding CKD development and dialysis dependency. For example, Prakash et al. found that 76.83% of patients fully recovered, though 10.8% progressed to CKD. (22) Gopalakrishnan et al. identified 35% of patients developing CKD, with 7.69% becoming dialysis dependent. (18) Mir et al. noted a CKD development rate of 21%, (24) while Pahwa et al. reported a 22.2% progression to CKD among their patients. (16) Tanwar et al. found that 51.3% of patients progressed to CKD. Saxena D et al also reported a very high rate of CKD development in 15 (30%), and 16 (32%) remaining dialysis dependant. (35)
In terms of non-recovery of renal function, patients who did not recover renal function by six weeks exhibited a substantially elevated risk of prolonged non-recovery, with an RR of 24.7 (95% CI: 3.4–179.5). (17) Saini et al., in their multivariate analysis, identified TMA as a significant predictor of non-recovery, with an odds ratio (OR) of 14.00 (95% CI: 1.13–172.58, P = 0.039). Other important but non-significant predictors included obstetric haemorrhage (OR: 7.50, 95% CI: 0.62–90.61, P = 0.11) and sepsis (OR: 4.28, 95% CI: 0.44–41.35, P = 0.20). (26) Sahay et al. further highlighted that clinical variables such as anuria, sepsis, TMA, and findings of cortical necrosis on renal biopsy were crucial predictors of non-recovery of renal function in PRAKI patients. (20)
Renal biopsy data
Renal biopsy was reported in 346 (15%) of patients. See Fig. 2. The most common finding was ACN in 172 (49.71%) followed by acute tubular necrosis in 63 (18.2%), TMA in 47 (13.5%), GN in 36 (10.4%) and ATIN in 13 (3.75%). The most common GN was LN (N = 14), followed by IGAN (N = 5), FSGS (N = 5), MPGN (N = 3), membranous nephropathy (N = 1), ANCA vasculitis (N = 2) and infections related GN (N = 1). Changes of endotheliosis were reported in 3 patients.
Fetomaternal outcome
The fetomaternal outcomes in PRAKI in India demonstrate significant variability across 25 different studies. See Table 4. Maternal mortality ranged from 2.5–34%. Larger studies, such as Sachan et al reported a maternal mortality rate of 34% (30) Patel et al. observed a 15% maternal mortality rate, (14) with Pahwa et al. reporting 18.51%. (16) Several other studies also reflected similar mortality rates. Perinatal outcomes were also significantly impacted. For example, Krishna et al. reported a perinatal mortality rate of 26.19%, (17) Mishra et al. observed fetal mortality as high as 67.3%. (21) The adverse fetal outcomes reported by Gopalakrishnan et al., which included intrauterine death (IUD) and stillbirths, were 54%. (18) Pre-term delivery was reported in several studies, with rates ranging from 13.9–58%. For example, Sandilya S and Eswarappa reported very high rates of premature deliveries with rates of 40%, and 58% respectively.(32, 20). Krishna et al. (17) reported several significant risk factors associated with increased mortality in patients with PRAKI. The risk of mortality was markedly higher in individuals with oliguria, sepsis, central nervous system involvement, hepatic dysfunction, and low platelet counts. Additionally, patients requiring multiple dialysis sessions had a significantly higher risk, with a relative risk (RR) of 2.96 (95% CI: 1.75–4.99, P = 0.001).
Table 4
Maternal and fetal outcomes
Sl, number | First author | Maternal mortality (N%) | Requirement of ICU (N%) | Perinatal mortality (N%) | IUD (N%) | Pre-mature deliveries, (N%) |
1 | Goplani KR et al, (10) | 13 (18.57%) | NR | NR | NR | NR |
2 | Najar MS et al, (11) | 8 (20%) | NR | NR | NR | NR |
3 | Arora N et al, (12) | 16 (28.1%) | NR | NR | NR | NR |
4 | Sivakumar V et al, (13) | 14 (23.72%) | NR | NR | NR | NR |
5 | Patel ML et al (14) | 9(15%) | NR | NR | NR | 25 (41.7%) |
6 | Pahwa N et al, (15) | 5 (18.51%) | NR | NR | NR | NR |
7 | Godara SM et al, (16) | 9 (15.78%) | NR | 28 (49.12%) | 3 (5%) | |
8 | Krishna A et al, (17) | 18 (18.36%) | 13 (13.8%) | 25 (26.19%) | NR | NR |
9 | Gopalakrishnan N et al, (18) | 10 (7.69%) | NR | Adverse fetal outcome (IUD + stillbirth) 70 (54%) | 29 (23%) | NR |
10 | Gullipali et al, (19) | 4 (8.3%) | | NR | 7 (14.7%) | 11 (22.9%) |
11 | Eswarappa et al, (20) | 18 (19%) | 99 (100%) | 14 (22%) | NR | NR |
12 | Mishra V et al, (21) | 17(32.69%) | 15 (28.85%) | Fetal mortality − 67.3% | 17 (32.69%) | NR |
13 | Prakash J et al, (22) | 25 (9.60%) | NA | 117 (45.17%) | NR | NR |
14 | Prakash J et al, (23) | 8 (6.1%) | NR | 30 (23%) | 23 (17.5%) | 54 (40.9%) |
15 | Mir M et al, (24) | 3 (11%) | NR | 3 (11%) | 2 (7.15%) | NR |
16 | Tanwar et al, (25) | 17 (28.3%) | 17 (31.7%) | NR | 14 (23.3%) | NR |
17 | Saini et al, (26) | 20 (25%) | NR | 19 (23.5%) | NR | NR |
18 | Chowdhary PK, (27) | 22 (20.56%) | NR | 15 (14.01%) | NR | NR |
19 | Banerjee A et al, (28) | 1 (2.7%) | 36 (all in ICU) | Total n = 14 (38.8%), Early RRT: 2 (14.29%), Standard : 12 (85.71%) | NR | 18 (50%) , Early 8 (44.44%), Standard 10 (55.56%) |
20 | Sahay M et al, (29) | 20 (5%) | NR | 30 (7.5%) | 42 (10.6%) | 45 (13.9%) |
21 | Sachan R et al, (30) | 51 (34%) | 149 (96.1%) | 56 (38.4%) (IUD + Still births) | 56 (38.4%) | 34 (23.3%) |
22 | Yadav S et al, (31) | 14 (23.5%) | 18 (33.3%) | 19 (37.3%) | 20 (39.2%) | 8 (15.7%) |
23 | Sandilya S, (32) | 7 (14%) | 50 (100%) | 6 (16%) | 12 (24%) | 20 (40%) |
24 | Kharkongor D et al, (32) | 22 (20%) | NR | NR | NR | NR |
25 | Saxena D et al, (34) | 9 (14.5%) | NR | NR | 16 (25.8%) | 12 (19.4%) |
IUD: Intrauterine deaths, ICU: Intensive care unit, RRT: Renal replacement therapy, NR: Not reported/not clear |
Figure 5 shows the visual graphical summary of the findings of the analysis.